2-[[6-甲氧基-4-(1-甲基乙基)-1,1-二氧并-3-氧代-1,2-苯并异噻唑-2(3H)-基]甲氧基]-9-[2-(1-哌啶基)乙氧基]-4H-吡啶并[1,2-a]嘧啶-4-酮 | 344930-95-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶并嘧啶类
• 中文名称: 2-[[6-甲氧基-4-(1-甲基乙基)-1,1-二氧并-3-氧代-1,2-苯并异噻唑-2(3H)-基]甲氧基]-9-[2-(1-哌啶基)乙氧基]-4H-吡啶并[1,2-a]嘧啶-4-酮
• 英文名称: SSR69071
• 英文别名: 6-Methoxy-1,1-dioxo-2-[[4-oxo-9-(2-piperidin-1-ylethoxy)pyrido[1,2-a]pyrimidin-2-yl]oxymethyl]-4-propan-2-yl-1,2-benzothiazol-3-one
• CAS: 344930-95-6
• 化学式: C₂₇H₃₂N₄O₇S
• 分子量: 556.64
• InChiKey: DRZXDZYWZSKFDL-UHFFFAOYSA-N

物化性质

• 溶解度：
  溶于二甲基亚砜

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  39
• 可旋转键数：
  9
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  126
• 氢给体数：
  0
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  2-氨基-3-羟基吡啶 在 sodium hydroxide 、 四丁基碘化铵 、 三乙胺 作用下， 以 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 、 丙酮 为溶剂， 反应 184.0h， 生成 2-[[6-甲氧基-4-(1-甲基乙基)-1,1-二氧并-3-氧代-1,2-苯并异噻唑-2(3H)-基]甲氧基]-9-[2-(1-哌啶基)乙氧基]-4H-吡啶并[1,2-a]嘧啶-4-酮
  参考文献：
  名称：

  A novel orally active inhibitor of HLE

  摘要：

  Human leukocyte elastase (HLE) is a serine proteinase, capable of degrading a variety of structural matrix proteins. SSR69071 2[(4-isoprop);1-6-methoxy-1,1-dioxido-3-oxo-1,2-benzisothiazol-2(3H)-yl)methoxy]-9-(2-piperidin-1-ylethoxy)-4H-pyrido[1,2-a]pyri- midin-4-one was selected as a novel orally active HLE inhibitor for treatment of chronic obstructive pulmonary diseases, asthma, emphysema, cystic fibrosis and several inflammatory diseases (WO 01/44245 Al) (J. Pharm. Exp. Ther., submitted for publication). (C) 2003 Editions scientifiques et medicales Elsevier SAS. All rights reserved.

  DOI：

  10.1016/s0223-5234(03)00046-1

文献信息

• SACCHARIN DERIVATIVES AS ORALLY ACTIVE ELASTASE INHIBITORS
  申请人：——

  公开号：US20030114449A1

  公开（公告）日：2003-06-19

  Orally active compounds of general formula (I) wherein R 1 is methyl, ethyl or 2-morpholino-ethyl group, R 2 is piperidino, morpholino or 4-methyl-piperazinyl group, n is 2 or 3 and their salts, solvates and hydrates.

  通式（I）中的口服活性化合物，其中R1为甲基、乙基或2-吗啉基乙基基团，R2为哌啶基、吗啉基或4-甲基哌嗪基团，n为2或3，以及它们的盐、溶剂合物和水合物。
• BLOOD TREATMENT METHOD AND BLOOD COLLECTION TUBE
  申请人：ARKRAY, Inc.

  公开号：EP3575791A1

  公开（公告）日：2019-12-04

  The method for treating collected blood to be used in a test for rare cells in blood, includes mixing the collected blood with an agent that increases the intracellular concentration of cAMP or an analogous compound thereof. The method for performing a test for rare cells in blood, includes using blood treated using the method according to the present disclosure as a blood sample to be subjected to the test.

  处理采集的血液以用于检测血液中的稀有细胞的方法包括将采集的血液与增加细胞内cAMP或其类似化合物浓度的药剂混合。进行血液中稀有细胞检测的方法，包括使用根据本公开的方法处理过的血液作为要进行检测的血样。
• Biomarkers and therapeutics targets for cognitive decline
  申请人：Schmechel Donald E.

  公开号：US20090232910A1

  公开（公告）日：2009-09-17

  Enrichment of S and Z polymorphisms of alpha-1-antitrypsin (AAT) in distinct subsets of patients with cognitive disorder (pre-existing affective disorders and APOE2 allele carriers) suggests that AAT variants are potential endophenotypes for Alzheimer Disease and related disorders of cognition, behavior and affect. Such disorders include ADD/ADHD, learning disabilities, ADEM, and susceptibility to brain injury in toxic/chemical/biological/immunological events. In Alzheimer Disease, S and Z alleles affect age of onset and low AAT levels define faster progression rate. Twenty to thirty percent of all dementia patients display AAT and/or We polymorphisms. Effects of AAT may involve inflammation of liver/lung, macrophage activation and iron and lipid metabolism. AAT, its regulation, and iron metabolism represent therapeutic targets and AAT can serve as a biomarker for vulnerability and disease progression.
• [EN] SELECTIVE INHIBITORS OF NEUTROPHIL ELASTASE FOR TREATING NEUROPATHIC PAIN AND CHRONIC PAIN STATES HARBOURING A NEUROPATHIC COMPONENT<br/>[FR] INHIBITEURS SÉLECTIFS DE L'ÉLASTASE NEUTROPHILIQUE POUR TRAITER DES ÉTATS DE DOULEUR NEUROPATHIQUE ET DE DOULEUR CHRONIQUE COMPRENANT UNE COMPOSANTE NEUROPATHIQUE
  申请人：RUPRECHT KARLS UNIVERSITÄT HEIDELBERG

  公开号：WO2016050835A2

  公开（公告）日：2016-04-07

  The present invention relates to selective inhibitors of neutrophil elastase, also called leukocyte elastase (LE) for use in the diagnosis, prognosis, prevention and/or treatment of neuropathic pain and chronic pain states harbouring a neuropathic component. The present invention further relates to pharmaceutical compositions and methods of diagnosing, prognosing, preventing and/or treating neuropathic pain and chronic pain states harbouring a neuropathic component.
• A novel orally active inhibitor of HLE
  作者：M Varga

  DOI：10.1016/s0223-5234(03)00046-1

  日期：2003.4

  Human leukocyte elastase (HLE) is a serine proteinase, capable of degrading a variety of structural matrix proteins. SSR69071 2[(4-isoprop);1-6-methoxy-1,1-dioxido-3-oxo-1,2-benzisothiazol-2(3H)-yl)methoxy]-9-(2-piperidin-1-ylethoxy)-4H-pyrido[1,2-a]pyri- midin-4-one was selected as a novel orally active HLE inhibitor for treatment of chronic obstructive pulmonary diseases, asthma, emphysema, cystic fibrosis and several inflammatory diseases (WO 01/44245 Al) (J. Pharm. Exp. Ther., submitted for publication). (C) 2003 Editions scientifiques et medicales Elsevier SAS. All rights reserved.